Order a test
Follow us
Order a test

News, publications
& more

05/26/2023

OncoHost To Present PROphet® Biomarker Model That Accurately Predicts Clinical Benefit to ICI-Based Treatment
05/25/2023

OncoHost to Present PROphet® Biomarker Model that Accurately Predicts Clinical Benefit to ICI-Based Treatment at ASCO 2023
05/25/2023

PROphet Biomarker Model Results to be Presented
05/04/2023

Other news to note for May 4, 2023
05/04/2023

OncoHost Licenses Biosensing Technology From BGN Technologies to Predict Immunotherapy Response
04/21/2023

The Impact of Proteomics on Precision Oncology
03/31/2023

Is ChatGPT Fast Becoming ChatMD? Introducing Generative AI To Healthcare
02/23/2023

Latest News: OncoHost announced official launch of PROphet non-small cell lung cancer (NSCLC) Test in the United States.
02/22/2023

AI/ML Enables Earlier Cancer Detection, Guided Treatment
02/20/2023

Health IT Product News Report February 2023
02/09/2023

Health IT Business News – February 9, 2023
02/09/2023

OncoHost lunches non-small cell lung cancer test in U.S.
02/04/2023

Beyond Biotech podcast 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine
02/02/2023

Israel is starting to win the battle with cancer
02/02/2023

Blood Test Offers Hope For Lung Cancer Patients
02/01/2023

OncoHost Launches PROphet NSCLC Cancer Test in the United States
02/01/2023

OncoHost Launches PROphet® NSCLC Test in the United States; Predictive Blood Test Guides First-Line Treatment Decisions for Advanced Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients
02/01/2023

OncoHost Launches NSCLC Test in the U.S.
02/01/2023

OncoHost Launches PROphet® NSCLC Test in the United States
01/24/2023

Oncohost partners with US research institutions to analyze resistance mechanisms in cancer
01/12/2023

OncoHost Wins 2023 BIG Innovation Award for PROphet® Platform
01/12/2023

Health IT Business News – January 12, 2023
01/10/2023

Texas Research Institute, TGen, OncoHost Partner to ID Lung Cancer Resistance Mechanisms
01/10/2023

New Study Combines AI And Multiomics Analysis To Understand Cancer Resistance Mechanisms
01/09/2023

Pharma – 2023 Health IT Predictions
12/14/2022

OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023
12/02/2022

Health Tech World Awards: Recognising the most impactful startups
11/17/2022

Health IT Business News – November 17, 2022
11/11/2022

OncoHost to present proteomics-based biomarker model for clinical benefit to immunotherapy in NSCLC patients at SITC 2022
10/05/2022

Health IT Hires, Appointments, and Who’s Hiring
10/03/2022

Appointments and advancements for Oct. 3, 2022
10/03/2022

OncoHost: Chris Dingman, James Whelan
10/03/2022

OncoHost preparing launch of proteomics diagnostics platform for cancer, immunotherapy
09/06/2022

“Be human” – Founders reveal how to secure “real” investment for your startup
09/05/2022

Novel Diagnostic Platform Predicts NSCLC Patient Response to Immunotherapy
08/29/2022

Proteins provide clue to predict cancer treatment outcome
07/27/2022

Singapore delegation meets Israeli startups in Tel Aviv
07/22/2022

Surveys and Reports Roundup
07/14/2022

Florida Cancer Specialists & Research Institute Participating in Global Clinical Trial Analyzing Patient Responsiveness to Immunotherapy Treatment
06/30/2022

NGS Solution Detects Aneuploidies, AI-Powered Biomarker Test for Urothelial Cancer
06/27/2022

SomaLogic Partners with OncoHost for Precision Cancer Diagnostics
06/27/2022

New Directions: What Innovations Are Coming Down the Pike for Lung Cancer?
06/23/2022

Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome
06/22/2022

DeciBio’s Peripheral Biomarkers Q&A with Dr. Ofer Sharon of OncoHost
06/21/2022

JITC Publishes OncoHost Study Identifying Predictive Proteomic Signature to Analyze Treatment Resistance in NSCLC Patients
06/17/2022

SomaLogic, OncoHost announce license agreement for the development of precision cancer diagnostics
06/16/2022

Health IT Business News – June 16, 2022
06/14/2022

SomaLogic, OncoHost sign agreement to develop precision cancer therapy
06/14/2022

SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics
06/13/2022

OncoHost Licenses SomaLogic Platform to Develop Tests to Predict Patient Response to Immunotherapies
06/13/2022

SomaLogic, OncoHost ink agreement to develop tests
06/13/2022

SomaLogic in licensing deal with OncoHost
06/13/2022

SomaLogic inks license deal with OncoHost to develop precision cancer diagnostics
05/16/2022

Digital health news, funding roundup in the prior week; May 16, 2022
05/13/2022

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology
05/13/2022

AI-Powered oncology platform raises $35 million Series C funding round
05/12/2022

Global Roundup: Medtronic Kicks Off Aortic Stenosis Study in Japan
05/12/2022

OncoHost nabs $35M in funding round
05/11/2022

FORTUNE Term Sheet Newsletter
05/11/2022

Personalized cancer therapy co OncoHost raises $35m
05/11/2022

OncoHost Raises $35M For Precision Oncology Diagnostic Solution
05/10/2022

Oncohost’s $35M series C predicts expansion of Prophet study
05/10/2022

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology
05/10/2022

Can OncoHost’s PROphet predict host response to cancer treatments? Investors are waiting to find out
05/10/2022

OncoHost Raises $35M in Series C Funding
05/10/2022

$35 Million In New Funding For AI To Personalize Cancer Treatment
05/10/2022

OncoHost Raises $35M in Series C Financing
05/10/2022

OncoHost Raises $35M in Series C Financing
05/10/2022

OncoHost Raises $35M for AI-Powered Precision Oncology Platform
05/10/2022

Osmind raises $40M for emerging mental health treatment EHR and more digital health fundings
05/10/2022

Israeli biotech startup OncoHost raises $35 million in funding to personalize cancer treatment using AI
05/09/2022

Israeli startups eye growing precision oncology market
05/05/2022

‘Bio’ food, precision oncology to take center stage at biomed summit in Tel Aviv
04/08/2022

PROPHETIC Study of Immunotherapy Diagnostic Adds New Site in Buffalo, NY
04/08/2022

In Brief This Week: Qiagen, Renalytix, OpGen, PerkinElmer, Avacta, Paige, More
04/06/2022

OncoHost enters trial partnership to evaluate resistance to immunotherapy
04/05/2022

OncoHost Announces AI-Based Clinical Trial Collaboration to Analyze Immunotherapy Resistance
03/23/2022

Nobel laureate Prof. Aaron Ciechanover to discuss advances in precision medicine
03/16/2022

Driving Progress in Personalized Cancer Therapy
03/14/2022

Lifting the veil of uncertainty around cancer treatments
03/02/2022

Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space
03/01/2022

Oncology Peer Review On-The-Go: Ofer Sharon, MD, Discusses OncoHost and PROPHETIC Trial for NSCLC
02/03/2022

3 Researchers Developing Innovative Strategies In Cancer Therapy
01/28/2022

2022 Predictions for AI and Machine Learning in Healthcare
01/24/2022

Next Israeli astronaut’s 35 experiments revealed
01/24/2022

Space meat and hummus: Israel finalizes experiments for upcoming ISS mission
01/17/2022

OncoHost Announces Interim Results From PROPHETIC Trial, Multicenter Assessment Of NSCLC Patient Response To Immunotherapy
12/20/2021

OncoHost Collaborates with Lung Biobank Heidelberg to Discover Lung Cancer Biomarkers
12/17/2021

Israeli research institute makes great contributions to cancer research
12/16/2021

Global Roundup: Aussie Biopharma Raises $25 Million to Expand in US
12/13/2021

OncoHost, Heidelberg University Hospital Strike Lung Cancer Biomarker Alliance
12/07/2021

Health IT Appointments and Hires
12/01/2021

OncoHost: David Gandara
11/15/2021

Dr. Ofer Sharon, CEO of OncoHost, Talks the Potential Impact of Precision Medicine on Cancer Therapy
11/01/2021

CTech’s 20 Minute Leaders Podcast Interview with Ofer Sharon, CEO of OncoHost
10/31/2021

OncoHost’s Algorithms Predict Cancer Patients Response To Treatments
09/20/2021

Oncohost platform predicts response to lung cancer therapy
08/20/2021

OncoHost Wins Frost & Sullivan 2021 Technology Innovation Leadership Award for Excellence in Best Practices
08/19/2021

Global Roundup: Sweden’s Cellink Rebrands as BICO and Other News
07/06/2021

OncoHost’s Focus on the Patient Offers Precision Oncology to Combat Cancer
06/22/2021

Oncohost opens trial sites for study evaluating its AI proteomics profiling technology
06/17/2021

Israel’s OncoHost, UK’s NHS to study cancer patient responses to immunotherapies
06/16/2021

NHS opens 8 clinical trial sites to assess cancer treatment
06/16/2021

NHS Opens Eight UK Clinical Trial Sites to Assess Cancer Patient Response to Immunotherapy in Collaboration with OncoHost
06/16/2021

NHS opens eight UK clinical trial sites to assess cancer patient response to immunotherapy in collaboration with OncoHost
06/14/2021

The Impact of Technology on Healthcare
05/21/2021

Which Israeli technologies will soon be going to space?
03/30/2021

How an AI tool predicts responses to cancer treatment
02/17/2021

Dr. Ofer Sharon, CEO of OncoHost, Discusses Technology to Improve Cancer Care
02/01/2021

January 2021 smiles upon Israeli startups: 4 new Unicorns and over $1B in funding
01/26/2021

Health IT Appointments and Hires
01/22/2021

OncoHost Secures $8 Million Series B Funding Round
01/22/2021

Oncohost nabs $8M series B round for AI-powered precision oncology platform
01/21/2021

OurCrowd leads $8M Series B in Israeli personalized cancer therapy startup
01/21/2021

Money on the Move: January 15-20
01/20/2021

The evolution of machine learning in oncology: an interview with Dr Ofer Sharon
01/20/2021

OncoHost Secures $8M in Series B Funding
01/19/2021

OncoHost raises $8 million to develop AI that predicts cancer treatment responses
01/19/2021

Israel-based OncoHost closes $8M in Series B funding to provide personalized cancer therapy for more effective treatment
01/19/2021

Israeli Startup OncoHost Raises $8M For AI Precision Oncology Platform
01/12/2021

Nobel prizewinner Ciechanover hails ‘much more precise’ cancer treatment
12/31/2020

OncoHost – Personalized cancer therapy for more effective treatment
12/08/2020

Dr. Ofer Sharon, CEO of OncoHost – Interview Series
11/15/2020

OncoHost Offers New Hope For Cancer Sufferers
11/12/2020

Israeli blood test offers better choices to fight cancer
11/04/2020

Oncohost platform improves immunotherapy response predictions
10/06/2020

OncoHost Data on Host Immunotherapy Response to be Presented This Week
08/07/2020

By Next Year, Will Doctors Finally Have The Technology To Fully Personalize Treatments For Lung Cancer Patients?
06/04/2020

PART 2: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients
06/04/2020

PART 1: Yuval Shaked, ASCO 2020: Host Response Profiling for Melanoma Patients
04/07/2020

Developing Personalized Strategies To Maximize Cancer Therapy Success
03/01/2020

Personalized Cancer Treatment, A Real Possibility?
02/23/2020

$8m in BIRD grants go to Israeli-US collaborations in agtech and health
02/18/2020

Backed by EU funds, Israeli researcher tackles treatment-resistant cancer
02/10/2020

Startup develops blood test that aims to undermine tumors’ resilience
02/05/2020

Top 5 Recent Advances In Israeli Cancer Research And Treatment
02/04/2020

Cancer Treatment Doesn’t Work on Everyone. One Israeli Doctor Explains Why.
01/26/2020

US-Israel Foundation To Invest $8M In 9 New Joint Initiatives
01/21/2020

OncoHost, RayBiotech Awarded $1 Million Grant for Precision Oncology
01/21/2020

OncoHost, RayBiotech Win $1M From BIRD Foundation
01/21/2020

OncoHost, RayBiotech Win $1M From BIRD Foundation
01/15/2020

New Israeli Tech Can Determine Specific Cancer Treatment for Patients
12/31/2019

Israeli algorithm may predict if cancer patients will respond to treatment
12/17/2019

Israeli Firm OncoHost Using Host Response Proteomics to Inform Cancer Therapy
12/08/2019

First-Of-Its-Kind Lab To Improve Personalized Cancer Therapy Opens In Israel
12/05/2019

Hillel’s Tech Corner: Cancer treatment personalized
05/27/2023

OncoHost to Present PROphet® Biomarker Model that Accurately Predicts Clinical Benefit to ICI-Based Treatment at ASCO 2023
05/04/2023

OncoHost Collaborates with BGN Technologies to Predict Cancer Patient Response to Anti-PD-1 Treatment with IcAR Biosensing Tech
02/01/2023

OncoHost Launches PROphet® NSCLC Test in the United States
01/11/2023

OncoHost Wins 2023 BIG Innovation Award for PROphet® Platform
01/10/2023

Baylor Scott & White Research Institute, TGen and OncoHost Announce New Research Study to Analyze Resistance Mechanisms in Lung Cancer
11/07/2022

OncoHost to Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022
10/03/2022

OncoHost Announces New Executive Appointments Ahead of Imminent Launch of its Precision Oncology Platform
06/21/2022

JITC Publishes OncoHost Study Identifying Predictive Proteomic Signature to Analyze Treatment Resistance in NSCLC Patients
06/13/2022

SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics
05/10/2022

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncology
04/05/2022

OncoHost Announces Clinical Trial Collaboration with Roswell Park Comprehensive Cancer Center to Analyze Immunotherapy Resistance
02/14/2022

OncoHost CEO to Present at 2022 BIO CEO & Investor Conference
01/12/2022

OncoHost Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy
12/13/2021

OncoHost Announces Collaboration with Heidelberg University’s Lung Research Biobank to Discover Lung Cancer Biomarkers
11/30/2021

OncoHost Welcomes UC Davis Professor, David Gandara, M.D., to Scientific Advisory Board
11/12/2021

OncoHost to Present Data at SITC 2021 on Predicting NSCLC Patient Response to Immunotherapy Utilizing Proteomic Profiling
09/13/2021

OncoHost Publishes Data Identifying Predictive Signature for Response to Immunotherapy in Lung Cancer Patients
08/18/2021

OncoHost Wins Frost & Sullivan 2021 Technology Innovation Leadership Award for Excellence in Best Practices
06/16/2021

NHS Opens Eight UK Clinical Trial Sites to Assess Cancer Patient Response to Immunotherapy in Collaboration with OncoHost
01/19/2021

OncoHost Secures $8 Million Series B Funding Round to Advance its AI-Powered Precision Oncology Platform
01/11/2021

OncoHost Welcomes Nobel Prize Winner to Scientific Advisory Board
11/09/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy in Melanoma Patients at SITC 2020
10/05/2020

OncoHost to Present Data on Predicting Host Response to Immunotherapy at the MAP 2020 Virtual Congress – ESMO
09/17/2020

OncoHost to Present Data on Host Response Profiling for NSCLC Patients at ESMO Virtual Congress 2020
03/14/2020

OncoHost to Present Data on Host Response Profiling for Melanoma Patients at 2020 ASCO Annual Meeting
01/21/2020

BIRD – Israel-U.S. Binational Industrial R&D Foundation to Invest $8 million in 9 New Projects
01/21/2020

OncoHost and RayBiotech Awarded $1 Million Grant From the BIRD Foundation to Advance Precision Oncology for Patients Receiving Immunotherapy
12/04/2019

OncoHost Opens First-of-its-Kind Proteomics Laboratory for Host Response Analysis for Cancer Therapy
10/31/2019

OncoHost: Nature Reviews Cancer Article Outlines Host Response Analysis as New Tool for Precision Medicine in Oncology
02/27/2023

A New Approach to Personalized Immunotherapy
11/29/2022

Bringing Hope to Patients with Stage IV Non–Small-Cell Lung Cancer
10/25/2022

This Time, It’s Personal
08/30/2022

Collaboration is the key to advancing cancer care
05/31/2022

How Can We Investigate Biomarkers For Lung Cancer Patients More Effectively?
03/22/2021

Revealing the Blind Spot in Cancer Treatment with Host Response Profiling
01/13/2021

Treating cancer with precision: It’s time for host response profiling
02/13/2020

Cancer Therapy in 2020: The promise of host-response profiling
04/27/2023

Analytical validation of the PROphet computational model for clinical benefit prediction and decision-making tool in metastatic NSCLC
12/03/2022

A novel plasma proteomic computational model for predicting therapeutic benefit from immune checkpoint inhibitors in non-small cell lung cancer
09/08/2022

Host Response To Immune Checkpoint Inhibitors Contributes To Tumor Aggressiveness
06/19/2022

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
12/10/2020

21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
08/15/2020

A proteomics-based biomarker discovery platform for predicting clinical response to immune checkpoint inhibitor therapy in non-small cell lung cancer
05/25/2020

A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.
10/23/2019

The pro-tumorigenic host response to cancer therapies
03/21/2015

Host effects contributing to cancer therapy resistance
05/29/2023

Join us at the BIO International Convention 2023
03/19/2023

Join us at the ASCO Annual Meeting 2023 – Booth #10085
03/16/2023

Join us at the AACR Annual Meeting 2023 – Booth #168
03/16/2023

ISLB & OncoHost Webinar: Addressing Unmet Needs in Predictive IO Biomarkers
01/11/2023

OncoHost Wins 2023 BIG Innovation Award for PROphet® Platform
12/29/2022

OncoHost is Presenting at PMWC 2023
12/29/2022

We’re attending JPM Healthcare Conference 2023
08/02/2022

Presentation: Plasma proteomic profiling as a precision oncology tool
04/04/2022

AI & Big Data – A Bright New Diagnosis? Roundtable
11/01/2021

Congratulations to the WINNERS of the Health Tech Digital Awards 2021!
09/30/2021

Winner of Best Poster Award in the Biomarker Category – ESMO 2021
09/27/2021

OncoHost: Semifinalist in 2021 Disruptive Technology Award Competition
View all

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
27518
T. (855) 950-2112
E. contact@oncohost.com

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
3057324
T. +972 485 37558
E. contact@oncohost.com

Please Note:
PROphet® NSCLC is currently available in all US states except NY
Order online
Order by fax
Order online
Login for existing users
Sign up for new users